이원석 교수 연구실
article|
인용수 0
·2025
1490P Infiltrative HCC defines a clinically and molecularly distinct subtype with poor clinical outcomes from atezolizumab plus bevacizumab
Hong Jae Chon, Won Suk Lee, Sun‐Hee Woo, SH Lee, I. Kim, Hyung Jun Kim, Chansik An, Su Woong Jung, G. Kim, H. Kang, Byung Woog Kang, J.S. Kim, Ho Yeong Lim, Il‐Jun Kang, Hye Yeon Yang, Woon Yong Kwon, Sung Chul Hwang, Chan‐Won Kim
Annals of Oncology
키워드
AtezolizumabBevacizumabHepatocellular carcinomaCarcinomaVascular endothelial growth factor